Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Breast Neoplasms 8Sarcoma 5Lung Neoplasms 5Urinary Bladder Neoplasms 4Neoplasms 4Lymphoma 4Hodgkin Disease 4Uterine Cervical Neoplasms 3Thyroid Neoplasms 3Thyroid Cancer, Papillary 3Rectal Neoplasms 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Lymphoma, Large B-Cell, Diffuse 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Hepatocellular 3Adenocarcinoma, Follicular 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Pleural Effusion, Malignant 2Neuroendocrine Tumors 2Mesothelioma 2Melanoma 2Lymphoma, B-Cell 2Liver Neoplasms 2Kidney Neoplasms 2Colonic Neoplasms 2

Interventions

lutetium Lu 177 dotatate 2copper dotatate CU-64 2Etoposide 2zimberelimab 1folfirinox 1famitinib 1cabozantinib 1abemaciclib 1Temozolomide 1Nivolumab 1Lutetium-177 1Lutetium 1Irinotecan 1Granulocyte Colony-Stimulating Factor 1Fluorodeoxyglucose F18 1Filgrastim 1Cytokines 1Cryotherapy 1Copper 1Cisplatin 1Carboplatin 1Acupuncture Therapy 1Acupressure 164Cu-DOTATATE 1177Lu-octreotide, DOTA(0)-Tyr(3)- 111-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Gastro-enteropancreatic neuroendocrine tumor × Fluorodeoxyglucose F18 × Clear all
NCT05709171 2023-11-22

Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms

Rigshospitalet, Denmark

Phase 2 Unknown
200 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡